Bruker Corporation

Bruker is positioned for a 2027 operating leverage cycle, with five consecutive quarters of bookings exceeding revenue and significant cost reductions. BRKR's margin expansion is driven by self-help initiatives, not volume, with non-GAAP operating margin rising to 16.3% and free cash flow rebounding sharply. Management expects backlog conversion to drive mid-single-digit organic growth and double-digit EPS expansion in 2027, supported by portfolio shifts toward drug discovery.

Bruker Corporation ( BRKR ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Joe Kostka Frank Laukien - Chairman, CEO & President Gerald Herman - Executive VP & CFO Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Luke Sergott - Barclays Bank PLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Lu Li - BofA Securities, Research Division Douglas Schenkel - UBS Investment Bank, Research Division Jack Meehan - Operon Research, LLC Kyle Boucher - TD Cowen, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Albert Hu - CTBC Financial Holding Co., Ltd. Presentation Operator Good morning, everyone, and welcome to the Bruker Corporation Third Quarter 2026 Earnings Conference Call.

Bruker NASDAQ: BRKR reported third-quarter 2026 revenue growth of 1.6% to $874 million, while non-GAAP earnings per share rose 24.4% year over year to $0.56 as cost-saving actions and favorable product mix supported margin expansion.

Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.